Advanced search
Publication Cover
Aging Health Volume 2, 2006 - Issue 6
Journal homepage
79
Views
0
CrossRef citations to date
0
Altmetric
Review

Non-Motor Symptoms in Parkinson’s Disease: An Underdiagnosed Problem

Sharon Muzerengi1 University Hospital Lewisham, London, UK
,
Helen Lewis1 University Hospital Lewisham, London, UK
,
Mark Edwards2 Movement Disorders Unit, Kings College Hospital, 9th Floor Ruskin Wing, Denmark hill, London, SE5 9RSUK Tel.: +44 207 346 8336; Fax: +44 208 333 3093; E-mail: [email protected];3 Guy’s King’s St. Thomas’ School of Medicine and Kings College, London
,
Emma Kipps2 Movement Disorders Unit, Kings College Hospital, 9th Floor Ruskin Wing, Denmark hill, London, SE5 9RSUK Tel.: +44 207 346 8336; Fax: +44 208 333 3093; E-mail: [email protected];3 Guy’s King’s St. Thomas’ School of Medicine and Kings College, London
,
Anuj Bahl2 Movement Disorders Unit, Kings College Hospital, 9th Floor Ruskin Wing, Denmark hill, London, SE5 9RSUK Tel.: +44 207 346 8336; Fax: +44 208 333 3093; E-mail: [email protected];3 Guy’s King’s St. Thomas’ School of Medicine and Kings College, London
,
Pablo Martinez-Martin5 Unit of Neuroepidemiology. National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
&
K Ray Chaudhuri1 University Hospital Lewisham, London, UK;2 Movement Disorders Unit, Kings College Hospital, 9th Floor Ruskin Wing, Denmark hill, London, SE5 9RSUK Tel.: +44 207 346 8336; Fax: +44 208 333 3093; E-mail: [email protected];3 Guy’s King’s St. Thomas’ School of Medicine and Kings College, London;4 National Parkinson Foundation Centre of Excellence, Kings CollegeLondon, UK
 show all
Pages 967-982 | Published online: 14 Dec 2006

Bibliography

  • Parkinson J : An essay on the shaking palsy [reprint of monograph published by Sherwood, Neely, and Jones, London, 1817].J. Neuropsychiatry Clin. Neurosci.14, 223–236(2002).
  • Hughes AJ , DanielSE, KilfordL, LeesAJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.J. Neurol. Neurosurg. Psychiatry55(3), 181–184(1992).
  • Movement Disorder Society Task Force on Rating Scales for Parkinson’s disease: The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov. Disord.18(7), 738–750(2003).
  • Olanow CW , WattsRL, KollerWC: An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines.Neurology56(Suppl. 5), S1–S88 (2001).
  • Global Parkinson’s disease Survey Steering Committee: Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov. Disord.17(1), 60–67(2002).
  • Chaudhuri KR , SchapiraAHV, Martinez-MartinP et al.: The holistic management of Parkinson’s using a novel non-motor symptom scale and questionnaire. Adv. Clin. Neurosci. Rehab.4, 20–24(2004).
  • Aarsland D , LarsenJP, TandbergE, Laake K: Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J. Am. Geriatr. Soc.48(8), 938–942(2000).
  • Schrag A , JahanshahiM, QuinnN: What contributes to quality of life in patients with Parkinson’s disease?J. Neurol. Neurosurg. Psychiatry69(3), 308–312(2000).
  • Findley L , AujlaM, BainPG et al.: Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov. Disord.18(10), 1139–1145(2003).
  • Hagell P , NordlingS, ReimerJ, Grabowski M, Persson U: Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Mov. Disord.17(6), 1213–1220(2002).
  • Pressley JC , LouisED, TangMX et al.: The impact of comorbid disease and injuries on resource use and expenditures in Parkinsonism. Neurology60(1), 87–93(2003).
  • Chaudhuri KR , YatesL, Martinez-MartinP: The non-motor symptom complex of Parkinson’s disease: time for a comprehensive assessment.Curr. Neurol. Neurosci. Rep.5, 275–283(2005).
  • Hely MA , MorrisJGL, ReidWGJ, TrafficanteR: Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years.Mov. Disord.20, 190–199(2005).
  • Shulman LM , TabackRL, RabinsteinAA, WeinerWJ: Non-recognition of depression and other non-motor symptoms in Parkinson’s disease.Parkinsonism Relat. Disord.8(3), 193–197(2002).
  • Chaudhuri KR , HealyDG, SchapiraAH: Non-motor symptoms of Parkinson’s disease: diagnosis and management.Lancet Neurol.5(3), 235–245(2006).
  • Chaudhuri KR , Martinez-MartinP, SchapiraAHV et al.: An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov. Disord.21(7), 916–923(2006).
  • Zgaljardic DJ , FoldiNS, BorodJC: Cognitive and behavioural dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions.J. Neural Transm.111, 1287–1301(2004).
  • Braak H , Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24, 197–210(2003).
  • Del Tredici K , BraakH: Idiopathic Parkinson’s disease: staging an α-synucleinopathy with a predictable pathoanatomy. In:Molecular mechanisms in Parkinson’s disease. Kahle P, Haass C (Eds). Landes Bioscience, Georgetown, TX USA, 1–32(2004).
  • Berg D : In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage.J. Neural Transm.113(3), 775–780(2006).
  • Berendse HW : Early diagnosis in PD: olfaction.Parkinsonism Relat. Disord.12(1), 1–2(2006).
  • Montgomery EB Jr, Baker KB, Lyons K et al.: Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology52, 757–762(1999).
  • Muller A , AbolmaaliND, HakimiAR et al.: Olfactory bulb volumes in patients with idiopathic Parkinson’s disease-a pilot study. J. Neural Transm.112, 1363–1370(2005).
  • Boeve BF , SilberMH, FermanTJ et al.: Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord.16, 622–630(2001).
  • Hawkes C : Olfaction in neurodegenerative disorders.Mov. Disord.18, 364–372(2003).
  • Ponsen MM , StoffersD, BooijJ, Van Eck-SmitBL, WoltersEC, Berendse HW: Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann. Neurol.56(2), 173–181(2004).
  • Sommer U , HummelT, CormannK et al.: Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov. Disord.19(10), 1196–1202(2004).
  • Comella CL , TannerCM, RistanovicRK: Polysomnographic sleep measures in Parkinson’s disease patients with treatment induced hallucinations.Ann. Neurol.34, 710–714(1993).
  • Ohayon MM , CauletM, PriestRG: Violent behaviour during sleep.J. Clin. Psychiatry58, 369–376(1997).
  • Rye DB : The two faces of eve. Dopamine’s modulation of wakefulness and sleep.Neurology63(3), S2–S7 (2004).
  • Schenck CH , BundlieSR, MahowaldMW: Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder.Neurology46, 388–393(1996).
  • Olson EJ , BoeveBF, SilberMH: Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases.Brain123, 331–339(2000).
  • Gagnon JF , BedardMA, FantiniML et al.: REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology59, 585–589(2002).
  • Iranzo A , MolinuevoJL, SantamariaJet al.: Rapid eye movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol.5 (7), 572–577(2006).
  • Stiasny-Kolster K , DoerrY, MollerJC et al.: Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain128(Pt 1), 126–137(2005).
  • Postuma RB , LangAE, Massicotte-Marquez J, Montplaisir J: Potential early markers of Parkinson’s disease in idiopathic REM sleep behaviour disorder. Neurology66(6), 796–797(2006).
  • Thanvi BR , MunshiSK, VijaykumarN, Lo TC: Neuropsychiatric non-motor aspects of Parkinson’s disease. Postgrad. Med. J.79(936), 561–565(2003).
  • Aarsland D , LarsenJP, Goek Lim N et al.: Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry67, 492–496(1999).
  • Lauterbach EC : The neuropsychiatry of Parkinson’s disease and related disorders.Psychiatr. Clin. North Am.27(4), 801–825(2004).
  • Burn DJ : Beyond the iron mask; towards better recognition and treatment of depression associated with Parkinson’s disease.Mov. Disord.17, 445–454(2002).
  • Remy P , DoderM, LeesA, TurjanskiN, BrooksD: Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system.Brain128(Pt 6), 1314–1322(2005).
  • O’Suilleabhain PE , SungV, HernandezC et al.: Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch. Neurol.61, 865–868(2004).
  • Lauterbach EC , FreemanA, VogelRL: Differential DSM-III psychiatric disorder prevalence profiles in dystonia and Parkinson’s disease.J. Neuropsychiatry Clin. Neurosci.16, 29–36(2004).
  • Nilsson FM , KessigLV, BolwigTG: Increased risk of developing Parkinson’s disease for patients with major affective disorders.Acta Psychiatr. Scand.104, 380–386(2001).
  • Schurmann AG , Van den Akker H, Ensinck KT et al.: Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology58, 1501–1504(2002).
  • Montgomery EB , LyonsK, KollerWC: Early detection of probable idiopathic Parkinson’s disease: II. A prospective application of diagnostic test battery.Mov. Disord.15, 474–478(2000).
  • Ahlskog JE : Challenging conventional wisdom, the etiologic role of dopamine oxidative stress in Parkinson’s disease.Mov. Disord.20(3), 271–282(2005).
  • Byrne KG , PfeifferR, QuigleyEM: Gastrointestinal dysfunction in Parkinson’s disease. A report of clinical experience at a single center.J. Clin. Gastroenterol.19, 11–16(1994).
  • Korczyn AD : Autonomic nervous system screening in patients with early Parkinson’s disease. In:Early diagnosis and preventive therapy in Parkinson’s disease. Przuntek H, Riederer P (Eds). Springer-Velag, Vienna, 41–48(1989).
  • Abbott RD , PetrovitchH, WhiteLR et al.: Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology57, 456–462(2001).
  • Edwards LL , PfeifferRF, QuigleyMM, HoffmanR, BallufM: Gastrointestinal symptoms in Parkinson’s disease.Mov. Disord.6, 151–156(2004).
  • Bernheimer H , BirkmayerW, Hornykiewicz O, Jellinger K, Seitelberger F: Brain dopamine and syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. Neurol. Sci.20, 415–455(1973).
  • Aarsland D , LarsenJP, Goek Lim N et al.: Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry67, 492–496(1999).
  • Lauterbach EC : The neuropsychiatry of Parkinson’s disease and related disorders.Psychiatr. Clin. North Am.27(4), 801–825(2004).
  • Shiba M , BowerJH, MaraganoreDM et al.: Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case–control study. Mov. Disord.15, 669–677(2000).
  • Weisskopf MG , ChenH, Schwarzschild MA, Kawachi I, Ascherio A: Prospective study of phobic anxiety and risk of Parkinson’s disease. Mov. Disord.18(6), 646–651(2003).
  • Aarsland D , EhrtU: The epidemiology of mental dysfunction in Parkinson’s disease. In:Mental Dysfunction in Parkinson’s disease III. Wolters E, Berendse HW, Stam CJ (Eds). VU University Press, Amsterdam, Holland, 95–108(2006).
  • Richard IH : Anxiety disorders in Parkinson’s disease.Adv. Neurol.96, 42–55(2005).
  • Singh A , AlthoffR, MartineauJ, JacobsonJ: Pramipexole, Ropinirole, and Mania in Parkinson’s disease.Am. J. Psychiatry162, 814–815(2005).
  • Starkstein SE , MaybergSE, PreziosiTJ et al.: Reliability, validity and clinical correlates of apathy in Parkinson’s disease. J. Neuropsychiatry4, 134–139(1992).
  • Pluck GC , BrownRG: Apathy in Parkinson’s disease.J. Neurol. Neurosurg. Psychiatry73, 636–642(2002).
  • Alves G , Wentzel-LarsenT, LarsenJP: Is fatigue an independent and persistent symptom in patients with Parkinson disease?Neurology10, 1908–1911(2004).
  • Brown RG , PluckG: Negative symptoms: the ‘pathology’ of motivation and goal-directed behaviour.Trends Neurosci.23(9), 412–417(2000).
  • Diederich NJ , GoetzCG, StebbinsGT: Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: focused review and a new integrative model.Mov. Disord.20, 130–140(2005).
  • Fenelon G , MahieuxF, HuonR et al.: Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain123, 733–745(2000).
  • Kipps CM , FungVSC, Grattan-SmithP, de MooreGM, MorrisJGL: Movement disorder emergencies.Mov. Disord.20, 322–334(2005).
  • Onofrj M , ThomasA, D’AndreamatteoG et al.: Incidence of RBD and hallucination in patients affected by Parkinson’s disease: 8-year follow-up. Neurol. Sci.23, S91–S94 (2002).
  • Moskovitz C , MosesH, KlawansHL: Levodopa-induced psychosis: a kindling phenomenon.Am. J. Psychiatry.135, 669–675(1978).
  • Goldman JG , GoetzCG, Berry-KravisE, LeurgansS, ZhouL: Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system.Arch. Neurol.61(8), 1280–1284(2004).
  • Reuter J , RaedlerT, RoseM et al.: Pathological gambling is linked to reduced activation in the mesolimbic reward system. Nature Neurosci.8(2), 147–148(2005).
  • Pezzella FR , ColosimoC, VanacoreN et al.: Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease. Mov. Disord.20(1), 77–81(2005).
  • Emre M : Dementia associated with Parkinson’s disease.Lancet Neurol.2(4), 229–237(2003).
  • Aarsland D , AndersenK, LarsenJP et al.: The rate of cognitive decline in Parkinson disease. Arch. Neurol.61(12), 1906–1911(2004).
  • Apaydin H , AhlskogE, ParisiJE, BoeveBF, DicksonDW: Parkinson disease neuropathology: late-developing dementia and loss of the levodopa response.Arch. Neurol.59, 102–112(2002).
  • Mattila PM , RinneJO, HeleniusH, DicksonDW, RöyttäM: α-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease.Acta Neuropathol.100, 285–290(2000).
  • Hurtig HI , TrojanowskiJQ, GalvinJ et al.: α-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology54, 1916–1921(2000).
  • Laakso MP , PartanenK, RiekkinenP et al.: Hippocampal volumes in Alzheimer’s disease, Parkinson’s disease with or without dementia: an MRI study. Neurology46, 678–681(1996).
  • Chaudhuri KR : Nocturnal symptom complex in PD and its management.Neurology61(3), S17–S23 (2003).
  • Lees AJ , BlackburnNA, CampbellVL: The nighttime problems of Parkinson’s disease.Clin. Neuropharmacol.11, 512–519(1988).
  • Garcia-Borreguero D , LarosaO, BravoM: Parkinson’s disease and sleep.Sleep Med. Rev.7, 115–129(2003).
  • Rye DB , JankovicJ: Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD.Neurology58, 341–346(2002).
  • Lai YY , SiegelJM: Muscle tone suppression and stepping produced by stimulation of midbrain and rostral pontine reticular formation.J. Neurosci.10(8), 2727–2734(1990).
  • Shouse MN , SiegelJM: Pontine regulation of REM sleep components in cats: integrity of the pedunculopontine tegmentum (PPT) is important for phasic events but unnecessary for atonia during REM sleep.Brain Res.571, 50–63(1992).
  • Dhawan V , HealyDG, PalS, Chaudhuri KR: Sleep-related problems of Parkinson’s disease. Age Ageing35, 220–228(2006).
  • Arnulf I , KonofalE, Merino-AndreuM et al.: Parkinson’s disease and sleepiness – an integral part of PD. Neurology58, 1019–1024(2002).
  • Abbott RD , RossGW, WhiteLR et al.: Excessive daytime sleepiness and the future risk of Parkinson’s disease. Mov. Disord.20(Suppl. 10), S101 (P341) (2005).
  • MacMahon D : Why excessive daytime sleepiness is an important issue in Parkinson’s disease.Adv. Clin. Neurol. Rehab.5(2), 46–49(2005).
  • Saper C , ChouTC, ScammellTE: The sleep switch: hypothalamic control of sleep and wakefulness.Trends Neurosci.24, 726–731(2001).
  • Crocker A , EspanaA, PapadopoulouBS et al.: Concommitant loss of dynorphin, NARP and orexin in narcolepsy. Neurology65(8), 1184–1188(2005).
  • Chaudhuri KR : Autonomic dysfunction in movement disorders.Curr. Opin. Neurol.14, 505–511(2001).
  • Benarroch EE : Central neurotransmitters and neuromodulators in cardiovascular regulation. In:Autonomic failure, 4th Edition. Mathias CJ, Bannister R (Eds). Oxford University Press, Oxford, UK, 37–44(1999).
  • Magerkurth C , SchnitzerR, BrauneS: Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life.Clin. Auton. Res.15, 76–82(2005).
  • Goldstein DS , HolmesC, LiST, BruceS, MetmanLV, CannonnRO 3rd: Cardiac sympathetic denervation in Parkinson’s disease. Ann. Int. Med.133(5), 338–347(2000).
  • Braune S , ReinhardtM, SchnitzerR, Riedel A, Lücking CH: Cardiac uptake of [123I] MIBG separates Parkinson’s disease from multiple systems atrophy. Neurology53, 1020–1025(1999).
  • Winge K , FowlerCJ: Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.Mov. Disord.21(6), 737–745(2006).
  • Herlofson K , LarsenJP: The influence of fatigue on health related quality of life in patients with Parkinson’s disease.Acta Neurol. Scand.107(1), 1–6(2003).
  • Karlsen K , LarsenJP, TandbergE, Jorgensen K: Fatigue in patients with Parkinson’s disease. Mov. Disord.14, 237–241(1999).
  • Alves G , Wentzel-LarsenT, LarsenJP: Is fatigue an independent and persistent symptom in patients with Parkinson’s disease?Neurology63, 1908–1911(2004).
  • Brown RG , JahanshahiM, QuinnN, MarsdenCD: Sexual function in patients with Parkinson’s disease and their partners.J. Neurol. Neurosurg. Psychiatry53, 480–486(1990).
  • Okun M , WalterBL, McDonaldWM et al.: Beneficial effects of testosterone replacement for the non motor symptoms of Parkinson’s disease. Arch. Neurol.59(11), 1750–1753(2002).
  • Tyvaert L , DevosD, RigotJM, BlondS, ReynsN, DesteeA: Sexual dysfunction and sub-thalamic stimulation in Parkinson’s disease.Parkinsonism Relat. Disord.11(2), 116 (2005).
  • Scherder E : Pain in Parkinson’s disease. Parkinson’s disease-related cognitive dysfunction.Parkinsonism Relat. Disord.12(1), 2 (2006).
  • Waseem S , Gwinn-HardyK: Pain in Parkinson’s disease. Common yet seldom-recognized symptom is treatable.Postgrad. Med.110(6), 33–40(2001).
  • Goetz CG , TannerCM, LevyM et al.: Pain in Parkinson’s disease. Mov. Disord.1(1), 45–49(1986).
  • Quinn NP , KollerWC, LangAE et al.: Painful Parkinson’s disease. Lancet1(8494), 1366–1369(1996).
  • Ford B , LouiseP, GreeneP et al.: Oral and genital pain syndromes in Parkinson’s disease. Mov. Disord.11(4), 421–426(1996).
  • Hillen ME , SageJI: Nonmotor fluctuations in patients with Parkinson disease.Neurology47(5), 1180–1183(1996).
  • Stacy M , BowronA, GuttmanM, HauserR: Identification of motor and nonmotor wearing – off in Parkinson’s disease: a comparison of patient questionnaire versus a clinician assessment.Mov. Disord.20(6), 726–733(2005).
  • Corrigan MH , DenahanAQ, WrightCE, RagualRJ, EvansDL: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.Depress. Anxiety11(2), 58–65(2000).
  • Byrne R , ChaudhuriKR: Depression a key nonmotor symptom of Parkinson’s disease.Prog. Neurol. Psychiatry10(5), 15–21(2006).
  • Rektorova I , RektorI, BaresM et al.: Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur. J. Neurol.10(4), 399–406(2003).
  • Singh A , AlthoffR, MartineauRJ, Jacobson J: Pramipexole, ropinorole and mania in Parkinson’s disease. Am. J. Psychiatry162(4), 814–815(2005).
  • Factor SA , FriedmanJH, LannonMC, OakesD, BourgeoisK, Parkinson Study group: Clozapine for treatment of drug-induced psychosis in Parkinson’s disease: results of the 12-week open label extension in the PSYCLOPS trial. Mov. Disord.16, 135–139(2001).
  • Ondo WG , TintnerR, Vuong Dat K, Lai D, Ringholz G: Double blind placebo controlled unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov. Disord.20, 958–963(2005).
  • Seemau P : Atypical antipsychotics mechanism of action.Can. J. Psychiatry47, 27–38(2002).
  • Factor SA , BrownD: Clozapine prevents recurrence of psychosis in Parkinson’s disease.Mov. Disord.7(2), 125–1231(1992).
  • Emre M , AarslandD, AlbaneseA et al.: Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med.351, 2509–2518(2004).
  • Ravina B , PuttM, SiderowfA, FarrarJT et al.: Donezepil for dementia in Parkinson’s disease: a randomised double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76(7), 934–939(2005).
  • Adler CH , CavinessJN, HentzJG et al.: Randomised trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov. Disord.18, 287–293(2003).
  • Hogl B , SaletuB, BrandauerE et al.: Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double blind, randomised, crossover, placebo controlled, polygraphic trial. Sleep25(8), 905–909(2002).
  • Ondo WG , FayleR, AtassiF, JankovicJ: Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial.J. Neurol. Neurosurg. Psychiatry76(12), 1636–1639(2005).
  • Lagalla G , MillevolteM, CapecciM, ProvincialiL, CeravoloMG: Botulinum toxin type A for drooling in Parkinson’s disease: a double blind, randomized, placebo-controlled study.Mov. Disord.21, 704–707(2006).
  • Raffaele R , VecchioI, GiammusoB et al.: Efficacy and safety of fixed dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson’s disease. Eur. Urol.41(4), 382–386(2002).
  • Eichhorn TE , OertelWH: Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy.Mov. Disord.16, 1176–1177(2001).
  • Parsons TD , RogersSA, BraatenAJ, Woods SP, Troster AI: Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a meta analysis. Lancet Neurol.5, 578–588(2006).
  • Kalteis K , StandhartdtH, Kryspin-ExnerI, BruckeT, VoltD, AlesF: Influence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson’s disease.J. Neural Transm.113(9), 1191–1206(2005).
  • Castelli L , PerozzoP, ZibettiM et al.: Chronic deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: effects on cognition, mood, anxiety and personality traits. Eur. Neurol.55(3), 136–144(2006).
  • Wermuth L , SorensenPS, TimmS et al.: Depression in idiopathic Parkinson’s disease treated with citalopram; a placebo controlled trial. Nord. J. Psychiatry52, 163–169(1998).
  • Leentjens AF , VreelingFW, LuijckxGJ et al.: SSRIs in the treatment of depression in Parkinson’s disease. Int. J. Geriatr. Psychiatry18, 552–554(2003).
  • Barone P , ScarzellaL, MarconiR et al.: Pramipexole versus sertaline in the treatment of depression in Parkinson disease: a national multicentre parallel-group randomized study. J. Neurol.253(5), 601–607(2006).
  • Fregni F , SantosCM, MyczkowskiML et al.: Repetitive transcranial magnetic stimulation is as effective as fluoxetine inn the treatment of depression in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry75(8), 1171–1174(2004).
  • Ondo WG , TintnerR, Vuong Dat K, Lai D, Ringholz G: Double blind placebo controlled unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov. Disord.20, 958–963(2005).
  • The Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N. Engl. J. Med.340, 757–763(1999).
  • Goetz CG , BlasucciLM, LeyrgansS, Pappert EJ: Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology55, 789–794(2000).
  • Hjort N , OstergaardK, DupontE: Improvement of sleep quality in patients with advanced Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus.Mov. Disord.19, 196–199(2004).
  • Ross W , PetrovitchH, AbbottRD, Tanner CM, Popper P, Masaki K: Association of olfactory dysfunction with risk of future Parkinson’s disease. Mov. Disord.20(10), P439 (2005) (Abstract).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.